최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Maturitas, v.32 no.3, 1999년, pp.161 - 170
Bjarnason, Ketil (Novo Nordisk A) , Cerin, Åsta (Karolinska Hospital, Department of Gynaecology and Obstetrics, Stockholm, Sweden) , Lindgren, Richard (University Hospital, Department of Gynaecology and Obstetrics, Linkö) , Weber, Tom (ping, Sweden)
AbstractObjectives: treatment with unopposed estrogen is known to increase the risk of endometrial hyperplasia, atypia, and carcinoma, and therefore the administration of a progestin during hormone replacement therapy (HRT) is recommended. The addition of a progestestin may cause unwanted side effec...
N. Engl. J. Med. Stampfer 325 756 1991 10.1056/NEJM199109123251102 Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the nurses’ health study
Paganini-Hill A. The risks and benefits of estrogen replacement therapy: Leisure World. Int J Fertil Menopausal Stud 1995;40 (suppl 1):54-62.
Pharmacoeconomics Wittingdon 5 419 1994 Hormone replacement therapy. 1. Pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency
Br. Med. Bull. Ellerington 48 401 1992 10.1093/oxfordjournals.bmb.a072553 HRT: Developments in therapy
Cancer Kurman 56 403 1985 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X The behaviour of endometrial hyperplasia. A long-term study of ‘untreated’ hyperplasia in 170 patients
Maturitas Wren 13 17 1991 10.1016/0378-5122(91)90281-T Compliance with hormonal replacement therapy
Acta. Obstet. Gynecol. Scand. Hammarback 64 393 1985 10.3109/00016348509155154 Cyclical mood changes as in the pre-menstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy
Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell D Jr, editor. Menopause: physiology and pharmacology. Chicago: Year Book Medical, 1986. p. 187-208.
David A, Czernoblisky B, Weinglass L. Long-Cyclic hormonal therapy in postmenopausal women. In: Berg G, Hammar M, editors. The modern management of the menopause. The Proceedings of the Seventh International Congress of the menopause. The Parthenon Publishing Group, 1994. p. 463-470.
10.1016/S0378-5122(97)81048-1 Englund D, Damm S, Hemmingsson E, Linden M, Ljungblad U, Nilsen T et al. Endometrial histology in long cycle HRT, for three years. Maturitas 1997;(suppl. 27): Abstract F 084.
Maturitas Lindgren 22 25 1995 10.1016/0378-5122(95)00913-6 Transdermal hormonal replacement therapy with transdermal progestin every second month
Obstet. Gynecol. Ettinger 83 693 1994 Cyclic hormone replacement therapy using quarterly progestin
Maturitas Hirvonen 21 39 1995 10.1016/0378-5122(94)00862-2 Can progestin be limited to every third month only in post-menopausal women taking estrogen?
Maturitas Boerrigter 24 63 1996 10.1016/0378-5122(95)01020-3 Endometrial response in estrogen replacement therapy quarterly combined with a progestogen
Acta Obstet. Gynecol. Scand. Einerth 61 373 1982 Vacum curettage by the Vabrar method. A simple procedure for endometrial diagnosis
Hendrickson M, Kempson R. In: Sternberg SS, editor. The Uterine Corpus in Diagnostic Surgical Pathology, vol. 2. New York: Raven Press, 1989. pp. 1591-1654.
N. Engl. J. Med. Whitehead 305 1599 1981 10.1056/NEJM198112313052701 Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium
Fertil. Steril. Moyer 59 992 1993 10.1016/S0015-0282(16)55916-0 Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes
J. R. Soc. Med. Whitehead 72 322 1979 10.1177/014107687907200504 Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy
Lancet Voigt 338 274 1991 10.1016/0140-6736(91)90417-N Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer
Am. J. Obstet. Gynecol. Archer 165 317 1991 10.1016/0002-9378(91)90084-5 Endometrial morphology in asymptomatic postmenopausal women
Am. J. Obstet. Gynecol. Woodruff 170 1213 1994 10.1016/S0002-9378(94)70129-6 Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group
Maturitas Meuwissen 15 33 1992 10.1016/0378-5122(92)90059-D Monitoring of oestrogen replacement therapy by vaginosonography of the endometrium
Mod. Pathol. Deligdisch 6 94 1993 Effects of hormone therapy on the endometrium
Maturitas de Cecco 15 199 1992 10.1016/0378-5122(92)90203-G Endometrial response in sequential cyclic therapy assessed with associated hysteroscopy and histology
10.1001/jama.1996.03530290040035 The writing group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Am Med Assoc. 1996;275:370-375.
Obstet. Gynecol. Grady 85 304 1995 10.1016/0029-7844(94)00383-O Hormone replacement therapy and endometrial cancer risk: a meta-analysis
Hum. Pathol. Brustman 6 664 1995 10.1016/0046-8177(95)90173-6 Nuclear organizer regions as markers of endometrial proliferation: A study of normal, hyperplastic and neoplastic tissue
Int. J. Gynecol. Pathol. Czerwenka 14 98 1995 10.1097/00004347-199504000-00002 Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic and malignant endometria
N. Engl. J. Med. Padwick 315 930 1986 10.1056/NEJM198610093151504 A simple method for determining the optimal dosage of progestin in postmenopausal women receiving estrogens
Lancet Sturdee 344 979 1994 10.1016/S0140-6736(94)91640-3 Is timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy?
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.